MicroRNA-588 is downregulated and may have prognostic and functional roles in human breast cancer

Yu, Miao; Zhang, Xin; Li, Hui; Zhang, Purong; Dong, Wei

doi:10.12659/msm.905126

Cited by 20 publications

(16 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the downregulation of miR-588 in OS was demonstrated to be associated with MSTS staging of patients with OS, which was consistent with the previously reported miRNA expression profile of OS (22). Similar findings in breast cancer showed that significant miR-588 downregulation could promote cancer cell proliferation and decrease cisplatin chemosensitivity (18). Furthermore, miR-588 downregulation also predicted the poor prognosis of patients with OS.…”

Section: Discussionsupporting

confidence: 92%

“…In the present study, miR-588 expression and MSTS staging were demonstrated to act as independent prognostic factors for OS. The prognostic value of miR-588 was also previously demonstrated in breast and prostate cancers (18,19). The prognostic value of miRNAs has drawn special attention in previous studies, and several miRNAs have been identified as independent prognostic indicators for various types of cancer (30).…”

Section: Discussionmentioning

confidence: 62%

“…Furthermore, miR-552-5p was reported to serve as a tumor promoter that could facilitate the development and progression of OS (17). A previous study demonstrated that miR-588 is downregulated in breast cancer and that it can inhibit the proliferation of breast cancer cells (18). The dysregulation and functional role of miR-588 in tumor cell development was observed in prostate cancer, gastric cancer and lung squamous cell carcinoma (19)(20)(21).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Downregulation of miR‑588 is associated with tumor progression and unfavorable prognosis in patients with osteosarcoma

Liang

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

Osteosarcoma (OS) is a primary malignant tumor characterized by a high metastatic potential and poor prognosis. The dysregulation of miR-588 has been demonstrated to serve crucial roles in the progression of numerous types of cancer. The present study aimed to investigate the expression and function of miR-588 in the development of OS. To do so, clinical samples were collected and analyzed, and in vitro experiments were conducted. A total of 104 patients with OS were recruited between 2012 and 2014. The expression of miR-588 was analyzed by reverse transcription quantitative PCR. The association between miR-588 expression and the clinicopathological characteristics and survival rate of patients with OS was evaluated. Furthermore, Cell Counting Kit-8 and Transwell assays were used to evaluate the effect of miR-588 on the proliferation and the migratory and invasive abilities of various OS cell lines. The results demonstrated that miR-588 expression in OS tissues and cells was significantly lower compared with normal tissues and cells. In addition, miR-588 expression was closely associated with the Musculoskeletal Tumor Society (MSTS) staging of patients with OS. miR-588 expression and MSTS staging were therefore considered as independent indicators for the prognosis of patients with OS. In addition, miR-588 downregulation significantly stimulated the proliferation and migratory and invasive abilities of OS cells. Taken together, these findings indicated that miR-588 may serve as an independent prognostic factor and tumor suppressor in OS.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 62%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Downregulation of miR‑588 is associated with tumor progression and unfavorable prognosis in patients with osteosarcoma

Liang

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…More specifically, our data suggest that low expression of miR-588 is a poor prognostic factor in GC patients. Consistent with our findings, miR-588 has been reported to be expressed at low levels in lung squamous cell carcinoma and breast cancer, and this low expression was associated with unfavorable patient prognosis [ 11 , 17 ]. In contrast, in human prostate cancer and ovarian cancer, miR-588 was shown to be overexpressed in tumor cells and tissues [ 14 ].…”

Section: Discussionsupporting

confidence: 91%

miR-588 is a prognostic marker in gastric cancer

Chen

Zhang

Gong

et al. 2020

Aging

View full text Add to dashboard Cite

In an effort to identify a novel microRNA (miRNA) as a gastric cancer (GC) treatment target and prognostic biomarker, we surveyed The Cancer Genome Atlas database and found that miR-588 expression is low in GC tissues. This was confirmed by real-time reverse transcription polymerase chain reaction assays of GC patient plasma samples and SGC7901 and MNK28 cells. A constructed miRNA-mRNA network showed that CXCL5, CXCL9, and CXCL10 are target genes of miR-588. Analysis of the miRWalk database revealed that miR-588 directly binds to CXCL5 and CXCL9. Overexpression of miR-588 reduced GC cell proliferation in vitro and in vivo . High expression of miR-588 inhibited Ki-67 expression in vivo . The FunRich database also showed that CXCL5, CXCL9, and CXCL10 are involved in immune responses, while the Database of Immune Cell Expression showed they are differentially expressed in CD8+ T cells. High expression of CXCL9 and CXCL10 correlated positively with infiltrating levels of CD4+ T and CD8+ T cells in stomach adenocarcinoma. High expression of miR-588, CXCL5, CXCL9, and CXCL10 was associated with prolonged survival of GC patients. These findings indicate that miR-588 is a biomarker for tumor-associated immune infiltration and a prognostic marker in GC patients.

show abstract

“…MiR-154 reduces the LSCC growth by inhibiting GALNT7 [ 19 ]. Meanwhile, it has been demonstrated that miR-588 serves as a tumor inhibitor in various cancers, such as lung and breast cancer [ 20 , 21 ]. Moreover, chemokine receptor 4 (CXCR4) is abnormally expressed in LSCC and contributes to LSCC malignant progression [ 22 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

Circular RNA ABCB10 contributes to laryngeal squamous cell carcinoma (LSCC) progression by modulating the miR-588/CXCR4 axis

Zhao

Wang

et al. 2021

Aging

View full text Add to dashboard Cite

Laryngeal squamous cell carcinoma (LSCC) is a common head and neck cancer with a high metastasis and poor prognosis. Circular RNAs (circRNAs) are a type of non-coding RNAs (ncRNAs) with regulatory function and broadly participate in cancer development. However, the correlation of circular RNA ABCB10 (circABCB10) with LSCC remains unclear. Here, we were interested in the role of circABCB10 in the modulation of LSCC progression. Our data demonstrated that the depletion of circABCB10 significantly inhibited the proliferation and induced the apoptosis of LSCC cells. Meanwhile, circABCB10 knockdown was able to remarkably reduce the invasion and migration of LSCC cells. Mechanically, circABCB10 served as a sponge for microRNAs-588 (miR-588) and miR-588 could target and down-regulated chemokine receptor 4 (CXCR4) expression in LSCC cells. The overexpression of CXCR4 or miR-588 inhibitor could reverse circABCB10 depletion-attenuated malignant phenotypes of LSCC cells. Functionally, the depletion of circABCB10 alleviated the tumor growth of LSCC cells in the tumorigenicity analysis of nude mice. The CXCR4 expression was decreased while the miR-588 expression was enhanced by circABCB10 depletion in vivo . Thus, we concluded that circABCB10 was involved in the malignant progression of LSCC by regulating miR-588/CXCR4 axis. Our finding provides new insights into the mechanism of circRHOT1 contributing to the development of LSCC. CircABCB10 and miR-588 may be used as potential targets for the treatment of LSCC.

show abstract

MicroRNA-588 is downregulated and may have prognostic and functional roles in human breast cancer

Cited by 20 publications

References 19 publications

Downregulation of miR‑588 is associated with tumor progression and unfavorable prognosis in patients with osteosarcoma

Downregulation of miR‑588 is associated with tumor progression and unfavorable prognosis in patients with osteosarcoma

miR-588 is a prognostic marker in gastric cancer

Circular RNA ABCB10 contributes to laryngeal squamous cell carcinoma (LSCC) progression by modulating the miR-588/CXCR4 axis

Contact Info

Product

Resources

About